U.S., April 26 -- ClinicalTrials.gov registry received information related to the study (NCT06386705) titled 'A Study of TSN084 in Patients With Advanced Malignant Tumors' on April 23.
Brief Summary: TSN084 is a novel type II kinase inhibitor with demonstrated anti-tumor effects in vitro and in vivo and targets multiple tyrosine kinases, such as c-MET, FLT3, TRK and serine/threonine kinase CDK8/19. This phase 1a/1b study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of TSN084 in advanced or metastatic malignancies in China.
Study Type: Interventional
Condition: Malignant Neoplasm
Intervention: Drug: TSN084
TSN084 wil...